March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago. 

Flyrcado is a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent. 

March 27, 2025 — Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies. The company will further expand use of Volt in EU markets throughout the second half of 2025. 

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA (finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025, in Chicago, IL, March 29-31, 2025.

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82 cm version of its Symphony 16F catheter.

March 17, 2025 – Ostial Corp., a privately held medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, has acquired the Wavella technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical, marking a strategic expansion in the coronary and peripheral markets, with product offerings now in the inpatient and office-based settings.

March 17, 2025 — Being born with a heart defect may be associated with an increased cancer risk for babies and their moms, according to new research published today in the American Heart Association’s flagship journal Circulation.

March 17, 2025 — GE HealthCare recently launched the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.

SCAI Scientific Sessions 2025 will take place May 1 to 3, at the Walter E. Washington Convention Center in Washington, DC.

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now